John E. And Lois A. Rogers Net Worth

The estimated Net Worth of John E. And Lois A. Rogers is at least $3.31 Миллион dollars as of 20 April 2015. John Rogers owns over 17,500 units of Aduro BioTech stock worth over $3,314,427 and over the last 10 years John sold ADRO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Rogers ADRO stock SEC Form 4 insiders trading

John has made over 2 trades of the Aduro BioTech stock since 2015, according to the Form 4 filled with the SEC. Most recently John bought 17,500 units of ADRO stock worth $297,500 on 20 April 2015.

The largest trade John's ever made was buying 147,058 units of Aduro BioTech stock on 20 April 2015 worth over $2,499,986. On average, John trades about 82,279 units every 0 days since 2015. As of 20 April 2015 John still owns at least 33,649 units of Aduro BioTech stock.

You can see the complete history of John Rogers stock trades at the bottom of the page.

What's John Rogers's mailing address?

John's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY, CA, 94710.

Insiders trading at Aduro BioTech

Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs и Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.

What does Aduro BioTech do?

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Complete history of John Rogers stock trades at Aduro BioTech

Aduro BioTech executives and stock owners

Aduro BioTech executives and other stock owners filed with the SEC include:

• William Greenman,
  Independent Director
• Ross Haghighat,
  Independent Director
• Eric Bjerkholt,
  Chief Financial Officer
• Noopur Liffick,
  IR Contact Officer
• Dolca Thomas,
  Director
• Michelle Griffin,
  Director
• Jerel Davis,
  Director
• Srinivas Akkaraju,
  Director
• Alan Glicklich,
  Chief Medical Officer
• Tom Frohlich,
  Chief Business Officer
• Eric Dobmeier,
  President, Chief Executive Officer, Director
• Thomas W. Dubensky,
  Chief Scientific Officer
• Gregory W Schafer,
  Chief Operating Officer
• Natalie Sacks,
  Chief Medical Officer
• Frank Mccormick,
  Director
• Gerald Chan,
  Director
• Stephen T Isaacs,
  President and CEO
• Stephanie Monaghan O Brien,
  Director
• Stephen A Sherwin,
  Director
• Dirk G. Brockstedt,
  Sr. VP of Research and Dev.
• Frank Karbe,
  Director
• Elsas Andrea Van,
  Chief Scientific Officer
• David Henry Mack,
  Director
• Celeste Ferber,
  SVP, GC and Secretary
• Dimitry Sa Nuyten,
  Chief Medical Officer
• Jennifer Lew,
  Sr. Vice President of Finance
• Venture (Vi) Investments Lt...,
  10% owner
• John E. And Lois A. Rogers,
  10% owner
• Keen Ltd Ultimate,
  10% owner
• Blaine Templeman,
  Chief Legal Officer
• James H Welch,
  See Remarks
• William G Kachioff,
  Interim CFO